Barclays’s Impact BioMedical IBO Stock Holding History

Barclays’s Portfolio IBO Stock Details IBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-89	Closed	-$2.24K	–	5533
2024 Q3	$2.24K	Buy	+89	New	+$2.66K	﹤0.01%	5077

Other funds holding IBO

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $50.1B AUM 35.17% 1-Year Est. Return

Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return

Barclays's IBO Position: Q4 2024 in Review

Barclays sold out of Impact BioMedical (IBO) in Q4 2024, closing a stake of 89 shares — an estimated $2.24K sold.

Barclays first reported a position in IBO in Q3 2024 and held it in 1 quarter. The position peaked at $2.24K in Q3 2024. 8 funds tracked by Wall St. Rank hold IBO as of Q4 2024.

Barclays reported no remaining Impact BioMedical position as of Q4 2024 after selling out during the quarter.
Barclays sold 89 Impact BioMedical shares in Q4 2024, an estimated $2.24K.
Barclays first reported a position in Impact BioMedical in Q3 2024 and held it in 1 quarter.
Barclays's Impact BioMedical position peaked at $2.24K in Q3 2024.
8 funds tracked by Wall St. Rank held Impact BioMedical as of Q4 2024.

Based on Barclays's 13F filing for Q4 2024, filed 13 Feb 2025.